← Back
Data updated: Jul 17, 2026
ACCORD
Pharma Pharmaceuticals
ACCORD is a pharmaceutical company with 2 FDA-approved products.
2021
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules
ACCORD's Key Drugs
ACCORD's core commercial portfolio centers on CAMCEVI ETM, CAMCEVI KIT — its most strategically important drugs approved in the last 15 years.
ACCORD's Recent FDA Approvals
ACCORD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ACCORD's Therapeutic Areas
Disease areas where ACCORD has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ACCORD Pipeline Snapshot
Active clinical trials for ACCORD across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CAMCEVI ETM leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2021-05-25
- Latest
- 2026-02-11
- Applications
- 2